Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (16)

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  3. HIV-2 molecular epidemiology in Spain: 30 years since the first case

    VIRUS EVOLUTION

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

2015

  1. Dolutegravir for the treatment of HIV-2 infection

    Journal of Clinical Virology, Vol. 64, pp. 12-15

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

2011

  1. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy

    Journal of Infection, Vol. 63, Núm. 5, pp. 382-390

2010

  1. Noncirrhotic portal hypertension in HIV-infected patients: Unique clinical and pathological findings

    AIDS, Vol. 24, Núm. 8, pp. 1171-1176

2009

  1. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

    AIDS, Vol. 23, Núm. 6, pp. 689-696

  2. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir:A harmacogenetic study

    Clinical Infectious Diseases, Vol. 48, Núm. 11

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2006

  1. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: Results from a large multicenter observational cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 41, Núm. 2, pp. 154-159

2002

  1. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

    Sexually Transmitted Infections, Vol. 78, Núm. 4, pp. 255-260